Ignacio Melero-rekin lankidetzan egindako argitalpenak (10)

2022

  1. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

2021

  1. Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576

  2. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

2020

  1. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

    OncoImmunology, Vol. 9, Núm. 1

  2. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

    Drug Safety, Vol. 42, Núm. 2, pp. 281-294

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain

    Cancer Immunology, Immunotherapy

  3. Introducción

    Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 12-17